Nuvation Bio Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.42 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2022-02-28
- Nuvation Bio Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-12-31 was $628.00K, a 59.39% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2020-12-31 was $394.00K.
- Nuvation Bio Inc. increase (decrease) in prepaid expense and other assets for fiscal 2021 was $2.42M, a 232.32% increase from fiscal 2020.
- Nuvation Bio Inc. increase (decrease) in prepaid expense and other assets for fiscal 2020 was $727.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|
| 2021-12-31 | $628.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.42M 10-K · filed 2022-02-28 | |
| 2021-09-30 | $1.79M 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | $394.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $727.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | $333.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |